Fifteen residues raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-22. Anything still debated is marked as such rather than presented as settled.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
== History == On 18 January 1839, the British East India Company landed Royal Marines at Aden. Their aims were to establish a supply port and stop attacks by Arab pirates against British shipping to India. The British Government thereafter considered Aden to be an important settlement due to its location, as the Royal Navy could easily access the port for resupply and repairs. Later, British influence extended progressively into the hinterland, both west and east, leading to the establishment of the Aden Protectorate.
=== Red blood cells === Vitamin A may be needed for normal red blood cell formation; deficiency causes abnormalities in iron metabolism. Vitamin A is needed to produce the red blood cells from stem cells through retinoid differentiation.
=== Calreticulin === Calreticulin – especially its lectin-like domain – interacts with MHC-I. The P domain faces the MHC-I peptide-binding site towards ERp57. This orientation makes it possible for tapasin to attach and secure MHC-I. This translocation of TAP facilitates its opening out into an ER luminal cavity, edged by standard membrane entry points such as those for tapasin and MHC-I. These two entry points facilitate the recruitment of MHC-I with optimal peptide loading and eventual release of MHC-I in T-cell surfaces for recognition.
Sources: en.wikipedia.org
== Structure == SrtB overall structure is conserved in different gram-positive bacteria. The overall structure of SrtB in S. aureus as shown in the figure, consists of a unique eight-stranded β-barrel core structure and a two-helix subdomain at the N-terminal end. SrtB is similar in structure to SrtA with rmsd of 1.25Å but SrtB has more peripheral helices It has an N-terminal helical bundle and an α-helix between β6 and β7. The N-terminal extension present in SrtB relative to SrtA is very significant. It is known to place the two termini on the same side of the protein. This is believed to result in a different orientation of the protein on the surface of the cell, potentially affecting substrate access.
Although a Mauthner cell is capable of bringing about an escape response all by itself, in the context of ordinary behavior other types of cells usually contribute to shaping the amplitude and direction of the response. Mauthner cells have been described as command neurons. A command neuron is a special type of identified neuron, defined as a neuron that is capable of driving a specific behavior all by itself. Such neurons appear most commonly in the fast escape systems of various species—the squid giant axon and squid giant synapse, used for pioneering experiments in neurophysiology because of their enormous size, both participate in the fast escape circuit of the squid. The concept of a command neuron has, however, become controversial, because of studies showing that some neurons that initially appeared to fit the description were really only capable of evoking a response in a limited set of circumstances. In organisms of radial symmetry, nerve nets serve for the nervous system. There is no brain or centralised head region, and instead there are interconnected neurons spread out in nerve nets. These are found in Cnidaria, Ctenophora and Echinodermata.
There are hydrophobic amino acids and hydrophilic amino acids in protein molecules. After protein folding in aqueous solution, hydrophobic amino acids usually form protected hydrophobic areas while hydrophilic amino acids interact with the molecules of solvation and allow proteins to form hydrogen bonds with the surrounding water molecules. If enough of the protein surface is hydrophilic, the protein can be dissolved in water. When salt is added to the solution, there is more frequent interaction between solvent molecules and salt ions. As a result, the protein and salt ions compete to interact with the solvent molecules with the result that there are fewer solvent molecules available for interaction with the protein molecules than before. The protein–protein interactions thus become stronger than the solvent–solute interactions and the protein molecules associate by forming hydrophobic interactions with each other. After dissociation in a given solvent, the negatively charged atoms from a chosen salt begin to compete for interactions with positively charged molecules present in the solution. Similarly, the positively charged cations compete for interactions with the negatively charged molecules of the solvent. This process is known as salting out. Soaps are easily precipitated by concentrated salt solution, the metal ion in the salt reacts with the fatty acids forming back the soap and glycerin (glycerol). To separate glycerin from the soap, the pasty boiling mass is treated with brine (NaCl solution).
In biology the term 'condensation' is used much more broadly and can also refer to liquid–liquid phase separation to form colloidal emulsions or liquid crystals within cells, and liquid–solid phase separation to form gels, sols, or suspensions within cells as well as liquid-to-solid phase transitions such as DNA condensation during prophase of the cell cycle or protein condensation of crystallins in cataracts. With this in mind, the term 'biomolecular condensates' was deliberately introduced to reflect this breadth (see below). Since biomolecular condensation generally involves oligomeric or polymeric interactions between an indefinite number of components, it is generally considered distinct from formation of smaller stoichiometric protein complexes with defined numbers of subunits, such as viral capsids or the proteasome – although both are examples of spontaneous molecular self-assembly or self-organisation. Mechanistically, it appears that the conformational landscape (in particular, whether it is enriched in extended disordered states) and multivalent interactions between intrinsically disordered proteins (including cross-beta polymerisation), and/or protein domains that induce head-to-tail oligomeric or polymeric clustering, might play a role in phase separation of proteins.
Sources: en.wikipedia.org
Though technically distinct from the alkanes, this class of hydrocarbons is referred to by some as the "cyclic alkanes." As their description implies, they contain one or more rings. Simple cycloalkanes have a prefix "cyclo-" to distinguish them from alkanes. Cycloalkanes are named as per their acyclic counterparts with respect to the number of carbon atoms in their backbones, e.g., cyclopentane (C5H10) is a cycloalkane with 5 carbon atoms just like pentane (C5H12), but they are joined up in a five-membered ring. In a similar manner, propane and cyclopropane, butane and cyclobutane, etc. Substituted cycloalkanes are named similarly to substituted alkanes – the cycloalkane ring is stated, and the substituents are according to their position on the ring, with the numbering decided by the Cahn–Ingold–Prelog priority rules.
=== Generic names === Ethylestrenol is the generic name of the drug and its INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name, and BANTooltip British Approved Name, while éthylestrénol is its DCFTooltip Dénomination Commune Française and ethylnandrol is its JANTooltip Japanese Accepted Name. The BANTooltip British Approved Name was formerly ethyloestrenol, but it was eventually changed.
The Kenny Report on Sky News Australia Sky News on Sky News Australia Today on the Nine Network 7.30 on ABC TV Sunrise on Seven Network The Project on Network 10 A Current Affair on Nine Network Q+A on ABC TV ABC News on ABC News In 2021 he starred in television adverts on behalf of the Australian government about COVID-19 vaccinations. In 2023 Coatsworth filled in as presenter of Today while regular host Karl Stefanovic took Christmas leave. His appointment left "plenty of noses out of joint" due to his perceived inexperience.
=== Injection valve === The injection valve is a motorized valve which links the mixer and sample loop to the column. Typically the valve has three positions for loading the sample loop, for injecting the sample from the loop into the column, and for connecting the pumps directly to the waste line to wash them or change buffer solutions. The injection valve has a sample loading port through which the sample can be loaded into the injection loop, usually from a hypodermic syringe using a Luer-lock connection.
A subset of progeria patients with heterozygous mutations of LMNA have presented an atypical form of the condition, with initial symptoms not developing until late childhood or early adolescence. These patients have had longer lifespans than those with typical-onset progeria. This atypical form is extremely rare, with presentations of the condition varying between patients with even the same mutation. The general phenotype of atypical cases is consistent with typical progeria, but other factors (severity, onset, and lifespan) vary in presentation.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.